We are proud to be among the innovative startups driving change in the pharmaceutical landscape, and we look forward to contributing to treatment advances for people suffering from hair loss. Preclinical models are supporting the potential of our topical formulation of sCD83, a soluble form of the human protein CD83, for stopping, and reversing, androgenetic alopecia and alopecia areata.

Explore the full guide to learn more about Mallia Therapeutics and the other remarkable startups that are revolutionizing the pharmaceutical industry in 2024: https://lnkd.in/dwmjJ-gm